Loading
The test for leftover cancer cells found none, down to the sensitivity of the assay (often one cell in 100,000 or a million). It is the deepest remission we can measure and is becoming a treatment goal and trial endpoint in blood cancers.
In CLL, undetectable MRD at the end of fixed-duration venetoclax therapy predicts years off treatment and defines when to stop; in myeloma, MRD negativity at 10^-5 or 10^-6 (by next-generation flow or sequencing) is accepted by the FDA as an early endpoint for accelerated approval and guides de-escalation trials; in ALL, converting MRD-positive to negative with blinatumomab (BLAST) was the basis of its approval; in AML, NPM1 or flow MRD decides who needs transplant. MRD-positive after therapy predicts relapse and triggers intensification. The depth (10^-4 versus 10^-6) matters and assays are not interchangeable.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Venetoclax.
Shares Complete response (CR) and partial response (PR), Maintenance therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares clonoSEQ, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
Shares Complete response (CR) and partial response (PR), Flow cytometry (immunophenotyping), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Blinatumomab, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Chronic lymphocytic leukaemia.
Shares Allogeneic stem cell transplant (allo-SCT), Blinatumomab, MRD / molecular residual disease testing, Acute lymphoblastic leukaemia.
Shares Blinatumomab, Venetoclax, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia.
Shares Flow cytometry (immunophenotyping), Blinatumomab, Minimal / molecular residual disease (MRD), Acute lymphoblastic leukaemia.
Shares Venetoclax, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Chronic lymphocytic leukaemia.